Tradestie Institutional Equity Comparison Engine

IBO vs SRZN โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

SRZN Overall Edge

SRZN Captures Institutional Edge (2โ€“2 Pillars ยท 5โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Surrozen, Inc. Common (SRZN) driven by superior Growth & Margin, Options & Structure while IBO counters with relative strength in Valuation, Momentum & Technical. Fundamentally, IBO trades at N/M Forward P/E with -12621.0% operating margin (+16.7% YoY revenue) versus SRZN at N/M Forward P/E and -485.4% operating margin (+408.6% YoY). In options structure, IBO sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against SRZN sits in CONSOLIDATION (5th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner IBO
IBO N/M vs SRZN N/M Fwd P/E
Growth & Margin Winner SRZN
Op Margin -12621.0% vs -485.4% ยท YoY +16.7% vs +408.6%
Momentum & Technical Winner IBO
1Y +872.5% vs +170.6% ยท 52W Pos 68% vs 80%
Options & Structure Winner SRZN
UNCLASSIFIED (N/A IV) vs CONSOLIDATION (5th %ile IV)
IBO NYSE American
Impact BioMedical, Inc.
Pharmaceutical Preparations
$4.96
-3.5% 1D
Market Cap $41.2M
1M Return +85.07%
1Y Return +872.55%
Forward P/E N/M
Unified AI Score
36.8 / 100 SELL
Tech 15.0 Fund 32.0 Flow 50.0 Mom 40.0
SRZN NASDAQ
Surrozen, Inc. Common
Biological Products, (No Disgnostic Substances)
$32.80
+3.76% 1D
Market Cap $603.7M
1M Return +39.93%
1Y Return +170.63%
Forward P/E N/M
Unified AI Score
32.8 / 100 SELL
Tech 50.0 Fund 32.0 Flow 64.0 Mom 40.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: IBO +872.55% SRZN +170.63% Spread: +701.92 pp (IBO Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period IBO Revenue SRZN Revenue IBO Op. Margin SRZN Op. Margin Margin Edge
FY2022 $0M $10M -6808.0% -354.7% SRZN
FY2024 N/A $10M N/A -239.7% SRZN
FY2025 $0M $0M -13381.2% -1210.6% SRZN

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: IBO (4) vs SRZN (5)
Institutional Metric IBO SRZN Criterion Row Winner
Market Capitalization Scale $41.2M $603.7M Larger Scale SRZN
Trailing P/E Ratio Valuation 0.4x N/M Lower Multiple IBO
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +16.7% +408.6% Higher Growth SRZN
Operating Margin (TTM) Profitability -12621.0% -485.4% Higher Margin SRZN
Net Profit Margin Profitability 4247.4% 0.0% Higher Margin IBO
Return on Equity (ROE) Capital Efficiency 71.2% -62.8% Higher ROE IBO
52-Week Range Position Momentum 68% ($0โ€“$7) 80% ($12โ€“$38) Stronger Trend SRZN
Beta / 30D Volatility Risk Regime -6.75ฮฒ ยท 120% Vol 1.21ฮฒ ยท 62% Vol Lower Realized Risk SRZN
Unified Institutional Score Composite Signal 36.8 / 100 (SELL) 32.8 / 100 (SELL) Higher Composite IBO

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full IBO vs SRZN Buy Guide
IBO UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live IBO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
SRZN CONSOLIDATION
37d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 5th %ile
IV Regime Compressed (<25th %ile)
Live SRZN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither IBO nor SRZN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.